Ubs Group Ag Terns Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 69,398 shares of TERN stock, worth $406,672. This represents 0.0% of its overall portfolio holdings.

Number of Shares

69,398

Previous 87,332 20.54%

Holding current value

$406,672

Previous $594,000 2.69%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$6.49 - $10.8 $116,391 - $193,687	-17,934 Reduced 20.54%	69,398 $578,000
Q2 2024 Aug 13, 2024	BUY	$4.54 - $8.2 $111,516 - $201,416	24,563 Added 39.13%	87,332 $594,000
Q1 2024 May 13, 2024	SELL	$4.86 - $8.19 $222,131 - $374,332	-45,706 Reduced 42.14%	62,769 $411,000
Q4 2023 Feb 09, 2024	BUY	$3.37 - $6.86 $292,957 - $596,346	86,931 Added 403.5%	108,475 $704,000
Q3 2023 Nov 09, 2023	SELL	$4.7 - $8.55 $148,195 - $269,590	-31,531 Reduced 59.41%	21,544 $108,000
Q2 2023 Aug 11, 2023	BUY	$7.35 - $13.29 $348,412 - $629,985	47,403 Added 835.74%	53,075 $464,000
Q1 2023 May 12, 2023	BUY	$7.91 - $12.0 $44,865 - $68,064	5,672 New	5,672 $67,000
Q3 2022 Nov 10, 2022	BUY	$1.87 - $6.42 $6,857 - $23,542	3,667 New	3,667 $22,000
Q1 2022 May 16, 2022	SELL	$2.83 - $6.7 $10,683 - $25,292	-3,775 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$5.65 - $10.73 $21,328 - $40,505	3,775 New	3,775 $27,000
Q2 2021 Aug 13, 2021	SELL	$12.26 - $22.0 $31,213 - $56,012	-2,546 Closed	0 $0
Q1 2021 May 12, 2021	BUY	$17.13 - $27.25 $43,612 - $69,378	2,546 New	2,546 $56,000

Others Institutions Holding TERN

# of Institutions

167

Shares Held

78.3M

Call Options Held

580K

Put Options Held

454K

View Full List

About Terns Pharmaceuticals, Inc.

Ticker TERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,613,800
Market Cap $220M
Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...

More about TERN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account